Arecor Therapeutics PLC (AREC)

Currency in GBP
64.00
+0.50(+0.79%)
Real-time Data·
AREC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
64.0064.00
52 wk Range
47.00100.00
Key Statistics
Bid/Ask
62.00 / 65.00
Prev. Close
63.5
Open
63.13
Day's Range
64-64
52 wk Range
47-100
Volume
13.95K
Average Volume (3m)
20.86K
1-Year Change
34.7368%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AREC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
275.50
Upside
+330.47%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Arecor Therapeutics PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 275.50
(+330.47% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Apr 13, 2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

AREC Income Statement

Compare AREC to Peers and Sector

Metrics to compare
AREC
Peers
Sector
Relationship
P/E Ratio
25.7x−6.7x−0.4x
PEG Ratio
0.25−0.130.00
Price/Book
3.7x3.9x2.6x
Price / LTM Sales
14.0x9.3x3.0x
Upside (Analyst Target)
333.9%136.4%49.7%
Fair Value Upside
Unlock−6.9%7.3%Unlock

Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company’s lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.22M3.24%777.54K
Other Institutional Investors
26.04M68.96%16.53M
Public Companies & Retail Investors
10.49M27.79%6.66M
Total
37.76M100.00%23.98M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Business Growth Fund Limited13.25%5,004,4793,178
Lombard Odier Asset Management (Europe) Ltd.8.12%3,064,4961,946

FAQ

What Is the Arecor Therapeutics (AREC) Stock Price Today?

The Arecor Therapeutics stock price today is 64.00 GBP.

What Stock Exchange Does Arecor Therapeutics Trade On?

Arecor Therapeutics is listed and trades on the London Stock Exchange.

What Is the Stock Symbol for Arecor Therapeutics?

The stock symbol for Arecor Therapeutics is "AREC."

What Is the Arecor Therapeutics Market Cap?

As of today, Arecor Therapeutics market cap is 23.98M GBP.

What Is Arecor Therapeutics's Earnings Per Share (TTM)?

The Arecor Therapeutics EPS (TTM) is 0.02.

When Is the Next Arecor Therapeutics Earnings Date?

Arecor Therapeutics will release its next earnings report on Sep 24, 2026.

From a Technical Analysis Perspective, Is AREC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Arecor Therapeutics Stock Split?

Arecor Therapeutics has split 0 times.

How Many Employees Does Arecor Therapeutics Have?

Arecor Therapeutics has 33 employees.

What is the current trading status of Arecor Therapeutics (AREC)?

As of Jul 08, 2026, Arecor Therapeutics (AREC) is trading at a price of 64.00 GBP, with a previous close of 63.50 GBP. The stock has fluctuated within a day range of 64.00 GBP to 64.00 GBP, while its 52-week range spans from 47.00 GBP to 100.00 GBP.

What Is Arecor Therapeutics (AREC) Price Target According to Analysts?

The average 12-month price target for Arecor Therapeutics is 275.50 GBP, with a high estimate of 300 GBP and a low estimate of 251 GBP. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +330.47% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.